1. In Vivo
  2. >>Growth

Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector

Israeli Industry And Investment Leaders Discuss Market Development

 
• By Kevin Grogan

While Israel has not wanted for early-stage scientific excellence, leading lights in the country's biotech space are working to create an ecosystem where clinical, regulatory and managerial expertise can develop.

Israel's life sciences sector is celebrated for its academic excellence and extensive basic R&D coming out of the likes of world-renowned establishments such as the Weizmann Institute and the Hebrew University of Jerusalem. There has historically been a lack of homegrown leadership to establish companies that can bridge the gap between discovery and getting products into late-stage trials, but this it is changing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

Three Steps To Investor Heaven For Founders: Articulate, Explain, Clarify

 
• By Ashley Yeo

Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

How Charl Van Zyl Is Reimagining Lundbeck

 
• By David Wild

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

More from In Vivo

UK Must Put Adoption On A Par With Innovation, AZ Tells BioWales Forum

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

 
• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.